| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() ERRATUM: AACR: Paclitaxel Carboplatin Combination Therapy Might Be as Effective as Mitoxantrone Alone for Patients With Hormone-Refractory Prostate Cancer There was an error in a recent article from our coverage of the American Association for Cancer Research 95th Annual Meeting. The original text read: "The major finding of our study is that hormone resistant prostate cancer must not be considered any more as chemoresistant," said presenter Philippe Chollet, MD, Centre Jean Perrin, Clermont-Ferrand, France. "Taxol carboplatin is a good and effective combination as taxotere alone is. In addition, prostate cancer must be treated in the same way as breast cancer." The corrected text now reads: "The major finding of our study is that hormone resistant prostate cancer must not be considered any more as chemoresistant," said presenter Philippe Chollet, MD, Centre Jean Perrin, Clermont-Ferrand, France. "Taxol carboplatin is a good and effective combination as mitoxantrone alone is. In addition, prostate cancer must be treated in the same way as breast cancer."
|